Caroline Seymour

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

The LimiTEC trial reveals that discontinuing teclistamab after 6-9 months yields comparable outcomes to continuous treatment in multiple myeloma patients.

Circulating tumor DNA (ctDNA) emerges as a crucial prognostic tool for lymphoma, enhancing event-free survival predictions and treatment response insights.

Pirtobrutinib demonstrates an impressive 81.6% response rate in CLL/SLL patients previously treated with BTK inhibitors, showcasing its efficacy and safety.

A novel treatment combining EIK1001 with pembrolizumab shows promising response rates in advanced non-small cell lung cancer, enhancing patient outcomes.

Combination therapy with datopotamab deruxtecan and rilvegostomig shows significant antitumor activity in advanced urothelial cancer patients.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

Tislelizumab enhances treatment outcomes in esophageal squamous cell carcinoma, showing improved response rates and survival compared to standard chemoradiotherapy.

Invikafusp alfa shows promising antitumor activity in TMB-H and MSI-H tumors resistant to immunotherapy, offering new hope for patients.

BNT111 combined with cemiplimab shows promising efficacy in treating PD-(L)1-relapsed melanoma, achieving significant response rates and manageable safety profiles.

Lenvatinib combined with pembrolizumab and chemotherapy shows no significant survival benefit over pembrolizumab plus chemotherapy in metastatic esophageal cancer.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa.

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

Elacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer.

Orca-T improved overall survival vs post-transplant cyclophosphamide in a retrospective analysis.

CTCm from circulating tumor cells correlated with outcomes in mCRPC patients treated with bavdegalutamide in the ARDENT trial.

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in the ASCEND trial.

Tislelizumab combined with irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin proved effective with manageable safety as frontline therapy for advanced HER2-negative, mismatch repair–proficient gastric and GEJ adenocarcinoma in the SYLT-023 trial.

The dual T-cell agonist invikafusp alfa achieved a 50% DCR in heavily pretreated anti–PD-1/PD-L1–resistant tumors, per findings at the 2024 SITC Annual Meeting.

Second-line treatment with lisocabtagene maraleucel in relapsed/refractory LBCL has safety and efficacy outcomes similar to those in the trials supporting its FDA approval.

T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in HR-positive, HER2-low/-ultralow metastatic breast cancer.

The phase 2 ZUMA-2 trial demonstrated that brexucabtagene autoleucel led to a high objective response rate in patients with relapsed/refractory mantle cell lymphoma.

Adding tafasitamab to lenalidomide and rituximab significantly reduced the risk of disease progression or death in patients with relapsed/refractory follicular lymphoma.

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer.

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.